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The characterization of cells with tumour initiating potential is significant for
advancing our understanding of cancer and improving therapy. Aggressive,
triple-negative breast cancers (TNBCs) are enriched for tumour-initiating cells
(TICs). We investigated that hypothesis that VEGF receptors expressed on TNBC
cells mediate autocrine signalling that contributes to tumour initiation. We
discovered the VEGF receptor neuropilin-2 (NRP2) is expressed preferentially
on TICs, involved in the genesis of TNBCs and necessary for tumour initiation.
The mechanism by which NRP2 signalling promotes tumour initiation involves
stimulation of the a6b1 integrin, focal adhesion kinase-mediated activation of
Ras/MEK signalling and consequent expression of the Hedgehog effector GLI1.
GLI1 also induces BMI-1, a key stem cell factor, and it enhances NRP2
expression and the function of a6b1, establishing an autocrine loop.
NRP2 can be targeted in vivo to retard tumour initiation. These findings reveal
a novel autocrine pathway involving VEGF/NRP2, a6b1 and GLI1 that contrib-
utes to the initiation of TNBC. They also support the feasibility of NRP2-
based therapy for the treatment of TNBC that targets and impedes the function
of TICs.
INTRODUCTION
The hypothesis that breast tumours harbor a population of
cells that can initiate tumourigenesis is supported by strong
experimental evidence (Al-Hajj et al, 2003; Baccelli & Trumpp,
2012; Gupta et al, 2009; Keller et al, 2012; Korkaya et al, 2011).
The frequency of such tumour-initiating cells (TICs) is high in
poorly differentiated tumours (Pece et al, 2010) and these cells
may be intimately associated with an epithelial mesenchymal
transition (EMT) and contribute to metastasis (DiMeo et al,
2009; Mani et al, 2008; Scheel et al, 2011). There is also evidence
that luminal-like cells without basal characteristics are capable
of initiating invasive breast tumours in mice (Kim et al, 2012b).
Regardless of their origin, much remains to be learned about the
mechanisms that enable the functions of TICs. Indeed, these
cells are attractive therapeutic targets, but they are notoriously
resistant to most standard chemotherapies (McDermott &
Wicha, 2010). Thus, elucidating the mechanisms that contribute
to the function of these cells is of obvious significance for
understanding the biology of breast cancer and improving the
clinical management of this disease.
OPEN
ACCESS
TRANSPARENT
PROCESS
Research Article
NRP2 in the initiation of breast tumours
(1) Department of Cancer Biology, University of Massachusetts Medical
School, Worcester, MA, USA
(2) Department of Cellular and Molecular Biochemistry, Center for Structural
Biology, University of Kentucky, Lexington, KY, USA
(3) The Jackson Laboratory, Bar Harbor, ME, USA
(4) Program in Molecular Medicine, University of Massachusetts Medical
School, Worcester, MA, USA
(5) Department of Bioscience and Nutrition, Center for Biosciences,
Karolinska Institute, Novum, Huddinge, Sweden
(6) Department of Anatomy and Cellular Biology, Tufts University School of
Medicine, Boston, MA, USA
*Corresponding author: Tel: þ1 508-856-1936; Fax: þ1 508-856-1310;
E-mail: hira.goel@umassmed.edu
488
 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. This is an open access article under
the terms of the Creative Commons Attribution License (CC BY 3.0), which permits use, distribution and reproduction
in any medium, provided the original work is properly cited. EMBO Mol Med (2013) 5, 488–508
A distinguishing feature of TICs is their self-sufficiency and
their use of specific signalling pathways to sustain their function
(DiMeo et al, 2009; Fillmore et al, 2010; Ginestier et al, 2010;
Kim et al, 2012a; Korkaya et al, 2011; Marotta et al, 2011;
Sansone et al, 2007; Scheel et al, 2011). Such pathways
contribute to their self-renewal and de-differentiation (Scheel
et al, 2011), and they are potential targets for therapeutic
intervention (Korkaya et al, 2011; Marotta et al, 2011). In this
context, VEGF receptors expressed on breast carcinoma cells
can mediate autocrine VEGF signalling that contributes to
tumour initiation and progression (Bachelder et al, 2001, 2002,
2003; Bae et al, 2008; Bagri et al, 2009; Barr et al, 2005; Bates
et al, 2003; Cao et al, 2008; Castro-Rivera et al, 2004; Gray et al,
2008; Hu et al, 2007; Lichtenberger et al, 2010; Matsushita et al,
2007; Mercurio et al, 2004). These findings challenge the notion
that the function of VEGF in cancer is limited to its role in
angiogenesis and that therapeutic approaches based on the
inhibition of VEGF and its receptors target only this function
(Ferrara, 2005).
Tumour cells express tyrosine kinase VEGF receptors
(VEGFR1 and VEGFR2) and neuropilins (NRPs), another family
of VEGF receptors. NRP1 and NRP2 were identified initially as
neuronal receptors for semaphorins, which are axon guidance
factors that function primarily in the developing nervous system
(Uniewicz & Fernig, 2008). The finding that NRPs can also
function as VEGF receptors and that they are expressed on
endothelial and tumour cells launched studies aimed at
understanding their contribution to angiogenesis and tumour
biology (Soker et al, 1998). NRPs have the ability to interact with
and modulate the function of VEGFR1 and VEGFR2, as well as
other receptors (Neufeld et al, 2002; Sulpice et al, 2008). There is
also evidence that NRPs are valid targets for therapeutic
inhibition of angiogenesis and cancer (Caunt et al, 2008; Goel
et al, 2012a; Gray et al, 2008; Pan et al, 2007). Importantly,
NRPs, functioning as VEGF receptors, have been implicated in
tumour initiation and the biology of tumour stem-like cells
(Beck et al, 2011; Glinka et al, 2012; Hamerlik et al, 2012). Of
note, autocrine VEGF/NRP1 signalling contributes to the self-
renewal of squamous skin tumours (Beck et al, 2011). Similarly,
the viability, self-renewal and tumourigenicity of glioblastoma
stem cells involve a VEGF/VEGFR2/NRP1 autocrine signalling
loop (Hamerlik et al, 2012). However, no studies to date have
implicated NRP2 in tumour initiation.
Despite the compelling evidence for the importance of VEGF/
NRP signalling in tumour initiation, little is known about the
mechanism by which this signalling affects the function of TICs.
Moreover, the possibility that NRPs function in concert with
other receptors besides the VEGFRs to drive tumour initiation
has not been investigated. Here, we sought to examine the
role of VEGF/NRP signalling in triple-negative breast cancers
(TNBCs) because they are characterized by a high frequency of
TICs (Idowu et al, 2012; Park et al, 2010) and high expression of
the a6b1 integrin (Gupta et al, 2011). Clinically, TNBCs are
defined by their lack of expression of the oestrogen receptor a
(ERa), progesterone receptor (PR) and HER2 (ERBB2), are
generally of high histological grade, poorly differentiated and
more aggressive compared to other subtypes of breast cancer
(Griffiths & Olin, 2012). This phenotype is consistent with the
observation that NRP2 expression in human breast cancer
correlates with aggressive disease and poor clinical outcome
(Yasuoka et al, 2009). These features also make TNBC an ideal
breast cancer sub-type to study how VEGF/NRP2 signalling
functions in tandem with a6b1 to promote the initiation of
breast tumours and to define the mechanism involved. Our
data reveal a novel autocrine signalling pathway mediated by
VEGF/NRP2 and a6b1 signalling that contributes to tumour
initiation. The nexus of this pathway is the Hedgehog (Hh)
effector GLI1 that is regulated by VEGF/NRP2 and that also feeds
back and regulates NRP2 expression and a6b1 function.
RESULTS
NRP2 is associated with tumour-initiating cells and
contributes to their function
Given that TICs involved in TNBC are characterized by high
expression of the a6b1 integrin (CD49f) (Meyer et al, 2010) and
our previous finding that this integrin associates with NRP2 in
TNBC (Goel et al, 2012b), we examined the expression and
function of NRP2 in this population of cells. Initially, we
compared NRP2 expression in sorted populations of TNBC cell
lines: SUM149 and SUM159. The CD44þ/CD24/EpCAMþ
population sorted from these lines has stem-like properties
and is able to initiate tumour formation much more readily than
the luminal population (CD44þ/CD24þ/EpCamþ) (Fillmore &
Kuperwasser, 2008). Indeed, the stem-like CD44þ/CD24/
EpCAMþ population expresses very high levels of NRP2
compared to the luminal population (Fig 1A). This stem-like
population also exhibits high expression of the a6b1 integrin
(Gupta et al, 2011). Subsequently, we assessed NRP2 expression
in normal mammary epithelial cells that had been transformed
with specific oncogenes: HMEC transformed with large T
antigen, hTERT and Ras (HMLE-PR) and MCF10A cells
transformed with T24 H-ras (MCF10A-AT). Oncogenic trans-
formation induced NRP2 expression in both cell types
concomitant with an increase in mammosphere formation
(Fig 1B and C), but it did not increase NRP1 expression (Fig 1B
and C).
To investigate the role of NRP2 in TICs and its relationship
to a6b1 further, we used primary tumour cells isolated from
freshly resected breast tumour biopsies. These epithelial cells
were sorted into a6high and a6low populations (Fig 1D and
Supporting Information Fig S1A). The a6high population, which
expressed high NRP2 (Fig 1D), formed mammospheres
significantly more than the a6low population (Supporting
Information Fig S1B). Importantly, mammosphere formation
was inhibited by a NRP2 blocking antibody (Fig 1E).
Additional evidence to implicate NRP2 in mammosphere
formation was obtained using SUM1315 cells, which have a
triple-negative phenotype. These cells were sorted into NRP2high
and NRP2low populations (Fig 1F and Supporting Information
Fig S1C and D). Approximately 10% of SUM1315 cells exhibit
high NRP2 expression, which is similar to the frequency
observed in freshly isolated breast tumour cells [Supporting
www.embomolmed.org Research Article
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Figure 1. NRP2 is associated with TICs and mediates mammosphere formation.
A. SUM149 and SUM159 cells were sorted by FACS into either stem (CD44þ/CD24/EpCAMþ) or luminal (CD44þ/CD24þ/EpCAMþ) populations. Expression of
NRP2 was analysed using qPCR. p¼ 0.0129 and p¼ 0.00499.
B,C. HMEC, HMLE-PR, MCF10A and MCF10AT cells were plated on low adhesion plates to measure their ability to form mammospheres. NRP2 and NRP1
expression was analysed by immunoblotting. Representative data from three independent experiments are shown. p¼0.0032 (for B) and p¼0.0077
(for C).
D,E. Epithelial cells freshly isolated from breast cancer biopsies were sorted by FACS into either a6high or a6low populations. Cell extracts were immunoblotted to
assess expression of NRP2, a6 and actin (D). These a6high and a6low populations were analysed for their ability to form mammospheres in the presence of
either control IgG or a NRP2 inhibitory Ab (E). These results are consistent using three different primary tumours (p¼ 0.0036).
F. The NRP2high population was sorted from SUM1315 cells by FACS and analysed for their ability to formmammospheres in the presence of either control IgG
or a NRP2 inhibitory Ab (p¼ 0.0049, three independent experiments).
G. The NRP2high and NRP2low populations of SUM1315 were isolated. The ability of the NRP2high population to formmammospheres in the presence of a VEGF-
NRP inhibitory peptide (C-furSema) or control peptide (C-Sema) was determined. Representative data from three independent experiments are shown
(p¼ 0.028). Scale bar¼ 100mm for all panels. For all panels, error bars represent the mean SD. Statistical differences between data groups were
determined using Student’s t-test.
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Information Fig S1C (Goel et al, 2012b)]. The NRP2high
population formed mammospheres significantly more than
did the NRP2low population (Supporting Information Fig S1E)
and a NRP2 Ab blocked mammosphere formation (Fig 1F).
These results were substantiated by the use of an inhibitory
peptide, C-furSEMA (Parker et al, 2010). This peptide, which
blocks the interaction of VEGF with NRPs specifically, inhibited
mammosphere formation by SUM1315 NRP2high cells (Fig 1G).
We also established two cell lines from the ascites fluid of breast
cancer patients. Both of these cell lines are able to form tumours
in vivo. NRP2 is necessary for these cells to form mammo-
spheres based on the use of a function blocking Ab (Fig 2A).
Importantly, mammospheres formed from these cells can be
passaged serially up to five times and there is an increase in
the expression of NRP2 and a6b1 integrin with each passage
(Fig 2B) suggesting a potential role for NRP2 in self-renewal.
Moreover, cells cultured in the presence of the NRP2 Ab failed to
form any mammospheres after the second passage (Fig 2C).
The involvement of NRP2 in tumour initiation was evaluated
in vivo using the NRP2high and NRP2low populations sorted from
SUM1315 cells. The ability of these populations to initiate
tumours in the mammary fat pad was compared by limiting
dilution. The NRP2high population formed tumours much more
readily than did the NRP2low population (Fig 2D). A significant
fraction of mice (66.6%) injected with only 103 NRP2high cells
formed tumours in contrast to the lack of tumour formation in
mice injected with the same number of NRP2low cells (Fig 2D).
We made use of a recently described mouse model of triple-
negative breast carcinoma in which the Rb, p53 and BRCA1
pathways were inactivated in the mammary epithelium using a
transgene encoding a fragment of the SV40 Large T-antigen
(T121) to inactivate pRb, along with conditional alleles of p53
and Brca1. These TgMFT121; Brca1f/f p53f/f; TgWAP-Cre mice
(hereafter referred to as TBP (T121, BRCA1, p53)), and they
develop highly penetrant, metastatic adenocarcinomas with a
triple-negative phenotype (Kumar et al, 2012). These tumours,
in marked contrast to mouse mammary tumour virus (MMTV)-
PyV-MT tumours, express abundant NRP2 (Fig 2E). Cells
derived from TBP tumours form mammospheres that are
dependent upon NRP2 (Fig 2F). Depletion of NRP2 in TBP
tumour cells using shRNA significantly attenuated their ability
to form tumours in mice (Fig 2G). To establish the role of
NRP2 in tumour initiation more definitively, we injected TBP
mice with a NRP2 inhibitory Ab (Anti-Nrp2B) at the time of
pregnancy, which triggers tumour onset in this transgenic
model. As shown in Fig 2H, the onset of these tumours was
significantly delayed by NRP2 inhibition.
VEGF/NRP2 and a6b1 contribute to FAK-mediated regulation
of BMI-1
The involvement of NRP2 in tumour initiation suggests that its
function may be linked to specific stem cell factors. Comparison
of the NRP2high and NRP2low populations sorted from SUM1315
cells revealed elevated expression of BMI-1, OCT-4 and SOX-2 in
the NRP2high population, although BMI-1 exhibited the largest
difference in expression between NRP2high and NRP2low
populations (Fig 3A and B). The relationship between NRP2
and BMI-1 was further confirmed using NRP2high and NRP2low
sorted populations from freshly isolated breast tumours
(Fig 3C). Moreover, the a6high/NRP2high population sorted
from the TBP transgenic cells exhibited markedly higher BMI-1
expression than did the a6low/NRP2low population (Fig 3D).
NRP2 is necessary for BMI-1 expression (Fig 3E), consistent
with our previous finding in prostate cancer (Goel et al, 2012a).
To investigate the role of VEGF in regulating BMI-1 expression,
either wild-type NRP2 or a NRP2 mutant lacking the b1 and b2
domains, which mediate VEGF binding (Geretti et al, 2008), was
expressed in the SUM1315 NRP2low population. This mutant
construct was unable to induce BMI-1 expression in contrast to
the wild-type construct (Fig 3F), providing evidence for the
requirement of autocrine VEGF signalling in regulating BMI-1.
The contribution of BMI-1 to mammosphere formation
was assessed by depleting NRP2 expression in the SUM1315
NRP2high population, which inhibited mammospheres, and
subsequently rescuing their formation by exogenous BMI-1
expression (Fig 3G). Similar results were obtained in soft agar
www.embomolmed.org Research Article
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Figure 2. NRP2 mediates self-renewal and contributes to tumour initiation.
A. Freshly harvested breast tumour cells from ascites (5104M and 5094M) were assayed for mammosphere formation in the presence of either control IgG or a
NRP2 Ab. Representative data from three independent experiments are shown (p¼ 0.0051; p¼ 0.00431).
B. Mammospheres from 5094M and 5104M cells were passaged serially up to four times and the surface expression of ITGA6 and NRP2 was quantified by flow
cytometry for each passage.
C. Mammospheres from 5094M and 5104M cells were passaged serially in the presence of either hIgG or a NRP2.
D. The NRP2high and NRP2low populations of SUM1315 cells were transplanted into the mammary fat pads of NSG mice using 10-fold serial dilution. The
formation of palpable tumours was used to evaluate tumour initiation. The summary chi-square statistic with one degree of freedom is 12.81 and the p-value
is 0.0003, indicating that NRP2high cells form significantly more tumours than NRP2low cells.
E. Formalin-fixed and paraffin-embedded sections from either TBP or MMTV-PyV-MT mouse mammary tumours (n¼3) were stained using a NRP2 Ab. Scale
bar¼25mm.
F. Primary cells isolated from four independent TBP tumours were used to assay mammosphere formation in the presence of either control IgG or a NRP2 Ab.
Representative data from three independent experiments are shown. p¼0.01; p¼ 0.003; p¼ 0.011; p¼0.0015.
G. Primary cells isolated from TBP mammary tumours that had been infected with either NRP2 or GFP shRNAs were transplanted into the mammary fat pads of
FVB mice (1105 cells per injection; 9 mice per group). The formation of palpable tumours was used to evaluate tumour initiation. Immunoblots show
downregulation of NRP2. The curve comparison was done using the Log-rank test. p¼ 0.02.
H. Pregnant female TBPmice either control (n¼ 15) or were injected i.p. with Anti-Nrp2B (twice weekly; n¼ 8). A total of four injections were given. The formation
of palpable tumours was used to evaluate tumour initiation. The curve comparisonwas done using Log-rank test. p¼ 0.03. Error bars represent themean SD
for the in vitro experiments. Statistical differences between data groups were determined using Student’s t-test.
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assays (Fig 3H), suggesting a role for the NRP2/BMI-1 pathway
in survival of cells in an anchorage-independent manner.
Recently, we reported that VEGF/NRP2 signalling regulates
the function of the a6b1 integrin (Goel et al, 2012b) and VEGF/
NRP2 signalling enables the a6b1 integrin and its ability to
activate focal adhesion kinase (FAK). We also reported that
the ability of VEGF/NPR2 to induce BMI-1 expression is FAK-
dependent in prostate cancer (Goel et al, 2012a). These findings
Research Article www.embomolmed.org
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Figure 2.
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are of particular interest since high expression of a6b1 (CD49f)
characterizes many tumour stem-like cells including those of the
breast (Friedrichs et al, 1995; Honeth et al, 2008; Lathia et al,
2010; Mulholland et al, 2009; Schober & Fuchs, 2011; Vieira
et al, 2012). Indeed, loss of a6b1 depleted BMI-1 mRNA and
protein expression in SUM1315 cells (Fig 3I).
In addition, we observed that the SUM1315 NRP2high
population exhibited significantly higher levels of activated
www.embomolmed.org Research Article
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FAK (pY397) than did the SUM1315 NRP2low population
(Fig 4A) and that this FAK activation is dependent on NRP2
(Fig 4B). Inhibition of FAK kinase activity diminished BMI-1
expression (Fig 4C) and expression of constitutively active FAK
in the SUM1315 NRP2low population induced FAK activation
and BMI-1 expression (Fig 4D). Importantly, expression of
constitutively active FAK increased the ability of these cells to
form mammospheres significantly (Fig 4D). Furthermore,
expression of pY397 FAK ismarkedly elevated in TBP transgenic
tumours compared to MMTV-PyV-MT tumours, and the a6high/
NRP2high population sorted from TBP tumour cells exhibited
markedly higher FAK activation than did the a6low/NRP2low
population (Fig 4E–F).
GLI1 is an effector of VEGF/NRP2 and a6b1 signalling that
regulates BMI-1
To determine the mechanism by which the activation of FAK by
VEGF/NRP2 and a6b1 induces BMI-1, we focused on GLI1, a Hh
pathway effector molecule because it is highly expressed in
normal human mammary stem/progenitor cells and contributes
to mammosphere formation, and the finding that GLI1 regulates
BMI-1 expression (Leung et al, 2004; Liu et al, 2006). Moreover,
the hedgehog/GLI1 pathway contributes to the function of
tumour-initiating cells in other cancer types (Clement et al,
2007; Peacock et al, 2007; Stecca et al, 2007; Varnat et al, 2009).
We discovered that depletion of NRP2 in SUM1315 cells
diminished GLI1 expression (Fig 5A), as well as its promoter
activity as assessed by a luciferase reporter construct (Fig 5B).
Unexpectedly, we found that GLI1 expression was also
dependent upon expression of a6b1 integrin (Fig 5C) and
FAK activation (Fig 5D). This signalling pathway was confirmed
in freshly isolated ascites cell lines (5094M and 5104M cells),
because expression of NRP2, BMI-1 and GLI1 was much higher
when these cells were cultured as mammospheres as compared
to adherent cells (Fig 5E). Interestingly, mammosphere culture
promotes an EMT phenotype as evidenced by the decreased
expression of E-cadherin and increased expression of vimentin
and fibronectin compared to adherent cells (Fig 5F). These
findings were substantiated by demonstrating that GLI1
expression is dramatically higher in the a6high/NRP2high
population sorted from TBP tumour cells compared to the
a6low/NRP2low population (Fig 5G). Similarly, antibody-
mediated inhibition of NRP2 reduced the expression of BMI-1
and GLI1 in TBP tumour cell lines (Fig 5H), as well as in primary
tumours isolated from TBP mice described in Fig 2H (Fig 5I).
The issue of whether GLI1 is induced by canonical or non-
canonical Hh signalling in our models was addressed initially by
examining the expression of Patched and Smoothened in both
SUM1315 and the cells that we isolated from human breast
tumours. All of these cells express Patched and Smoothened
(Fig 6A) and exogenous Shh increased their ability to form
mammospheres (Fig 6B). However, down-regulation of
Smoothened did not impact NRP2 expression, in contrast to
down-regulation of GLI1, suggesting that a non-canonical
pathway is the major driver of this autocrine loop (Fig 6C).
Smoothened down-regulation did reduce GLI1 expression in
LNCaP prostate cancer cells proving the efficacy of the
smoothened shRNAs (Fig 6C). The finding that activated FAK
increased GLI1 expression also supports non-canonical Hh
signalling (Fig 6D).
To define the signalling pathway connecting NRP2/VEGF and
integrin/FAK signalling to expression of GLI1 and BMI-1, we
investigated the role of Ras because Ras is known to regulate
non-canonical GLI1 activation (Lauth & Toftgard, 2007; Stecca
et al, 2007; Varnat et al, 2009). Moreover, Ras is a downstream
effector of integrin/FAK signalling (Guan, 2010; Schaller, 2010)
supporting our finding that integrin (a6b1) signalling regulates
GLI1 expression (Fig 5C). Indeed, expression of a dominant
negative form of Ras in the SUM1315 NRP2high population
reduced expression of GLI1 and BMI-1 significantly (Fig 6E), and
knock-down of Ras itself but not Smoothened reduced
GLI1 expression (Fig 6F). The role of NRP2-mediated Ras
activation in tumour initiation is supported by the finding
that expression of a constitutively-active Ras construct in
NRP2low SUM1315 cells promoted tumour formation (Fig 6G).
To assess the contribution of GLI1 in Ras-induced mammo-
sphere formation, we down-regulated GLI1 expression in
NRP2low SUM1315 cells expressing constitutively-active Ras
Research Article www.embomolmed.org
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Figure 3. VEGF/NRP2 signalling promotes mammosphere formation by regulating BMI-1.
A,B. Expression of BMI-1, OCT-4 and SOX-2 was quantified by qPCR in the NRP2high and NRP2low populations of SUM1315 cells and the expression pattern of
BMI-1 was verified by immunoblotting. Representative data from three independent experiments are shown. p¼0.15; p¼ 0.05; p¼ 0.04.
C. Expression of VEGF, BMI-1 and actin was compared by immunoblotting in the NRP2high and NRP2low populations isolated from breast cancer biopsies. These
results are consistent using three different biopsies.
D. Cells isolated from four independent TBP tumours were sorted by FACS into either a6high/NRP2high or a6low/NRP2low populations. Cell extracts from these
subpopulations were immunoblotted to measure expression of NRP2, BMI-1 and actin.
E. NRP2 expression was depleted by shRNAs in NRP2high SUM1315 subpopulation and BMI-1 expression was assessed by immunoblotting. Representative data
from three independent experiments are shown.
F. Either wild-type NRP2 or DVEGF-NRP2 constructs were expressed in the NRP2low SUM1315 subpopulation and the effect on BMI-1 expression was
determined by immunoblotting. Representative data from two independent experiments are shown.
G. Either a control vector or a BMI-1 containing vector was expressed in the NRP2high SUM1315 subpopulation that had been depleted of NRP2 expression and
the ability of these cells to form mammospheres was assayed. p¼ 0.023; p¼ 0.026 (two independent experiments).
H. The same populations of cells described in (G) were used to measure growth in soft agar. p¼0.019; p¼0.029 (two independent experiments).
I. SUM1315 cells were transfected with either a6 integrin or GFP shRNAs and the expression of a6, BMI-1 and actin was analysed by immunoblotting (left
panel). BMI-1 mRNA expression was quantified in these by qPCR (right panel). Representative data from three independent experiments are shown
(p¼0.007; p¼0.0025). Scale bar¼ 100mm for all panels. Error bars represent the mean SD for all panels. Statistical differences between data groups
were determined using Student’s t-test.
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and observed a significant inhibition of mammosphere forma-
tion (Fig 6H).
The possibility existed that FAK induces GLI1 expression by
inhibiting Suppressor of Fused (SuFu), a negative regulator of
GLI1. This possibility is supported by the observations that the
regulation of GLI1 by NRPs is dependent on SuFu (Hillman et al,
2011) and that oncogenic Ras enhances GLI1 activation by
suppressing SUFU (Kasai et al, 2008). However, down-
www.embomolmed.org Research Article
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Figure 4. FAK mediates the ability of NRP2 to promote mammosphere formation.
A. Extracts from the NRP2high and NRP2low populations of SUM1315 cells were immunoblotted with Abs specific for NRP2, p-FAK (pY397) or actin.
B. NRP2 expression was depleted by shRNAs in NRP2high SUM1315 population and FAK phosphorylation (pY397) expression was assessed by immunoblotting.
C. The NRP2high SUM1315 population was treated with a FAK inhibitor (PF-573228) and the effect on BMI-1 expression was determined by immunoblotting.
D. A constitutively active FAK construct was expressed in the NRP2low population of SUM1315 cells and the effect on BMI-1 expression (left panel) and
mammosphere formation (middle and right panels) was determined. The above experiments were repeated at least twice. Scale bar¼100mm. Error bar
represents the mean SD. Statistical differences between data groups were determined using Student’s t-test. p¼0.029.
E. Formalin-fixed and paraffin-embedded sections from either TBP or MMTV-PyV-MT mouse mammary tumours (n¼4) were stained using an Ab specific
for phosphorylated FAK (pY397). Scale bar¼ 25mm.
F. Cells isolated from four independent TBP tumours were sorted by FACS into either a a6high/NRP2high or a6low/NRP2low populations and immunoblotted
to determine the relative expression of p-FAK and FAK.
EMBO Mol Med (2013) 5, 488–508  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 495
regulation of SUFU increased mammosphere formation only
slightly (Fig 7A) indicating the involvement of other Ras
signalling pathways. One of the major signalling pathways
activated by Ras is the ERK pathway, and Ras-MEK signalling
plays an important role in GLI1 regulation of human cancer cells
(Lauth & Toftgard, 2007; Stecca et al, 2007; Varnat et al, 2009).
We observed comparable levels of mammosphere inhibition by
DN-Ras and the MEK inhibitor U0126 (Fig 7B). Expression of a
constitutively active form of MEK increased mammosphere
formation (Fig 7C), suggesting a role of Ras/MEK signalling in
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regulation of the GLI pathway. We also confirmed that BMI-1
was dependent upon GLI1 by expressing a dominant negative
GLI1 in SUM1315 NRP2high cells and observing reduced BMI-1
expression (Fig 7D). Similarly, GLI1 increased BMI-1 expression
in the NRP2low population of cells isolated from human breast
tumours (Fig 7E). Moreover, exogenous GLI1 rescued BMI-1
from the inhibitory effect of dominant-negative Ras, suggesting
that GLI1 is downstream of Ras (Fig 7F).
To establish the role of GLI1 in NRP2-mediated tumour
initiation, we expressed GLI1 in the SUM1315 NRP2low cells and
assayed their ability to form orthotopic tumours. Expression of
GLI1 decreased the incidence of tumour-free survival signifi-
cantly demonstrating that GLI1 is sufficient to compensate for
low NRP2 expression in tumour initiation (Fig 7G). Moreover,
down-regulation of GLI1 or inhibition of NRP2 in SUM1315
NRP2high cells significantly decreased tumour initiation
(Fig 7H).
More definitive data to evaluate the role of GLI1 in tumour
initiation and its relationship to NRP2 were obtained using a
transgenic mouse model of breast cancer in which GLI1 is
expressed under the regulation of the MMTV promoter (Fiaschi
et al, 2009). These GLI1-induced tumours exhibit expansion of a
population of epithelial cells expressing the progenitor cell
markers keratin 6 and BMI-1 (Fiaschi et al, 2009). Initially, we
compared the expression of VEGF, NRP2 and BMI-1 in MMTV-
GLI1 tumours with MMTV-PyMT tumours and observed
dramatically higher expression of these molecules in the
MMTV-GLI1 tumours (Fig 8A). The fact the expression of
VEGF and NRP2 was elevated in response to GLI1 expression
suggested the existence of an autocrine loop in which VEGF/
NRP2 and a6b1 regulate GLI1 and GLI1 regulates their
expression and function. To explore this hypothesis, we
assessed whether GLI1 regulates NRP2 expression. Indeed,
the data reveal regulation of NRP2 by GLI1 as evidenced by the
induction of NRP2 in SUM1315 NRP2low cells that express
exogenous GLI1 (Fig 8B) and reduced NRP2 expression
in response to GLI1 depletion in SUM1315 NRP2high cells
(Fig 8C).
The existence of an autocrine loop implies that GLI1 should
impact the function of the a6b1 integrin and FAK activation.
This possibility is supported by our finding that exogenous GLI1
expression in SUM1315 NRP2low cells increased adhesion to
laminin but not collagen and that this increased adhesion is
inhibited by an a6 function-blocking Ab (Fig 8D). Similarly,
depletion of GLI1 expression in SUM1315NRP2high cells reduced
adhesion to laminin but not to collagen (Fig 8E–F). GLI1
depletion in SUM1315 NRP2high cells and in the NRP2high
population sorted from breast tumour specimens reduced FAK
activation (Fig 8G).
We found that NRP2 has a GLI1 binding consensus sequence
in its promoter region, as well as an AP1 site that has been
shown to be important for regulating NRP2 expression (Goel
et al, 2012a). To evaluate the relative contribution of GLI1 and
AP1 binding sites to NRP2 promoter activity, we generated
luciferase reporter constructs in which either one or both of
these sites were mutated. We observed significant inhibition of
promoter activity when either site wasmutated and a synergistic
effect when both sites were mutated (Fig 8H).
Finally, we assessed the role of NRP2 in MMTV-GLI1
tumourigenesis. For this purpose, we used freshly harvested
tumour cells from two MMTV-GLI1 transgenic mice and
depleted NRP2 expression using shRNAs. The ability of these
cells to form orthotopic tumours in the mammary fat pad was
evaluated. A significant increase in tumour-free survival was
observed in NRP2-depleted cells compared to control cells
providing evidence for the importance of NRP2 in GLI1-
mediated tumourigenesis (Fig 8I).
NRP2 is a potential therapeutic target for triple-negative
breast cancer
Based on the findings that NRP2 plays an important role in
tumour initiation, we evaluated the potential of a function-
blocking NRP2 Ab (Anti-Nrp2B) to impact established tumours.
Treatment of mice harboring orthotopic SUM1315 tumours with
Anti-Nrp2B reduced tumour size significantly (Fig 9A). This
reduction in tumour size was associated with a reduced Ki-67
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Figure 5. NRP2 induces expression of GLI1.
A,B. NRP2 expression was depleted in SUM1315 and the effect on GLI1mRNA expression was quantified by qPCR (A: p¼0.015; p¼ 0.01) and on GLI1 promoter
activity by a luciferase reporter assay (B: p¼ 0.0045; p¼ 0.005).
C. Expression of the a6 integrin in SUM1315 cells was diminished by shRNA and the effect on GLI1 mRNA expression was quantified by qPCR. p¼0.01;
p¼0.004 (three independent experiments).
D. A constitutively active FAK construct was expressed in the NRP2low population of SUM1315 cells the effect on GLI1mRNA expression was quantified by qPCR.
The above experiments were repeated at least twice (p¼0.002).
E,F. mRNA expression of NRP2, GLI1, BMI-1 (E) and E-cadherin, vimentin and fibronectin (F) was compared between adherent and mammosphere cultures of
5094M and 5104M cells, which were isolated from ascites fluid. For panel E, the p-values for 5094M are 0.01 (NRP2), 0.02 (BMI-1), 0.01 (GLI1); and for
5104M they are 0.015 (NRP2), 0.02 (BMI-1), 0.02 (GLI1). For panel F, p-values are 0.01, 0.01 (for E-Cad); 0.006, 0.03 (for vimentin); 0.001, 0.004 (for
fibronectin).
G. Cells isolated from four independent TBP tumours were sorted by FACS into either a6high/NRP2high or a6low/NRP2low populations and GLI1 expression in these
populations was quantified by qPCR. p¼ 0.004 (for 1029); p¼ 0.002 (for 1113); p¼ 0.003 (for 1142); p¼ 0.02 (for 1308).
H. Tumour cells isolated from two independent TBP tumours were plated on low-attachment plate to formmammospheres in the presence of either Anti-Nrp2B
or control IgG. GLI1 and BMI-1 expression in these mammospheres was quantified by qPCR. p¼0.01,p¼ 0.005 (for 1029); p¼0.025, p¼ 0.001 (for
1308).
I. Tumour extracts from control or NRP2-antibody-treated TBP females were analysed for expression of GLI1 and BMI-1 by qPCR. Tumours from three
independent mice from each group were analysed. Error bars represent the mean SD for all panels. Statistical differences between data groups were
determined using Student’s t-test.
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expression (Fig 9B). Surprisingly, NRP2 inhibition had no
significant effect on angiogenesis as assessed by CD31 staining
(Fig 9B and C). To validate the existence of the proposed
pathway in clinical specimens, we quantified the expression of
VEGF, NRP2 and GLI1 in 32 TPN and 35 non-TPN human breast
tumour specimens by qPCR. The results obtained reveal that
triple-negative breast tumours express significantly more of
these molecules than non-triple-negative breast tumours
(Fig 9D). Also, we analysed the expression of phospho-FAK
by immunoblotting extracts from 21 triple-negative and 21 non-
triple-negative breast tumours. The densitometric analysis of
these immunoblots is provided in Fig 9E and it demonstrates
that triple-negative breast tumours express significantly more
phospho-FAK than non-triple-negative breast tumours.
Collectively, the data presented reveal a novel autocrine
signalling pathway that contributes to the initiation of TNBCs
that is amenable to therapeutic intervention. This pathway is
mediated by the surface receptors VEGF/NRP2 and a6b1
integrin, which activate FAK/Ras signalling culminating in the
enhanced expression of GLI1 and the consequent induction of
BMI-1 (Fig 9F).
DISCUSSION
This study reveals a novel autocrine signalling pathway
involving VEGF/NRP2 and the a6b1 integrin that contributes
to the initiation of TNBC. Although other studies have
demonstrated the importance of autocrine VEGF/NRP signalling
in tumour initiation (Beck et al, 2011; Hamerlik et al, 2012), no
study to date had defined a mechanism that links this signalling
to tumour initiation. The nexus of the pathway we define is the
Hh target GLI1, which is regulated by concerted VEGF/NRP2
and a6b1 signalling. Importantly, GLI1 can enhance NRP2
expression and the function of the a6b1 integrin, establishing
this autocrine pathway. A critical feature of GLI1 in this context
is its ability to induce BMI-1, a transcriptional repressor that has
been implicated in the function of mammary tumour stem cells
(Glinsky et al, 2005; Liu et al, 2006). Given that NRP2 can be
targeted effectively in vivo by Ab inhibition (Caunt et al, 2008),
our findings support the feasibility of NRP2-based therapy for
TNBC because such therapy would dismantle this autocrine
loop and impede the function of TICs.
Arguably, the identification and characterization of cells that
have tumour initiating potential is one the most significant
problems in advancing our understanding of breast and other
cancers and improving therapy. TNBC has been reported to
harbour a higher frequency of such TICs than many other breast
cancer sub-types (Idowu et al, 2012; Park et al, 2010; Polyak &
Weinberg, 2009) consistent with the hypothesis the frequency of
TICs increases with tumour grade and that such cells are
associated with metastatic potential (Park et al, 2010; Pece et al,
2010; Polyak & Weinberg, 2009). To date, several studies have
identified key signalling pathways that contribute to the
function of breast cancer stem or TICs (DiMeo et al, 2009;
Fillmore et al, 2010; Ginestier et al, 2010; Kim et al, 2012a;
Korkaya et al, 2011; Marotta et al, 2011; Polyak & Weinberg,
2009; Sansone et al, 2007; Scheel et al, 2011). A strength of our
study is that we link an autocrine signalling pathway involved in
tumour initiation directly to the regulation of a key stem cell
factor (BMI-1) that has been implicated in self-renewal (Liu et al,
2006) and in the EMT (Song et al, 2009). Moreover, BMI-1
expression has been associated with TNBC (Wang et al, 2012).
These observations, therefore, are consistent with the fact that
TNBC exhibits EMT characteristics (Jeong et al, 2012) and that
VEGF/NRP signalling can induce an EMT (Mak et al, 2010).
Our data implicate NRP2 as a VEGF receptor that has a critical
role in the initiation of TNBC. More specifically, we show that
NRP2 has a causal role in the ability of breast cancer cells to form
mammospheres in vitro and initiate tumours in vivo. A critical
result supporting this conclusion is that NRP2 inhibition delayed
the onset of tumours in a mouse model of TNBC (Fig 2H).
Interestingly, other recent studies have highlighted the impor-
tance of autocrine VEGF/NPR1 signalling in the initiation of skin
tumours and glioblastomas (Beck et al, 2011; Hamerlik et al,
2012). Although our study affirms the importance of autocrine
VEGF/NRP signalling in tumour initiation, it is the first such
study to implicate NRP2.
Our demonstration that the a6b1 integrin functions in concert
with NRP2 to drive autocrine VEGF signalling is significant
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Figure 6. NRP2 induction of GLI1 is mediated by non-canonical FAK/Ras signalling.
A. Smoothened and PatchedmRNA expression was quantified in SUM1315, UMBrC, 5094M and 5104M cells. Fold change was calculated relative to the value for
Smoothened expression in SUM1315 cells, which was set at 1.
B. These cells were stimulated with Shh conditioned media and the effect on their ability to form mammospheres was quantified. p¼0.005 (for SUM1315);
p¼0.01 (for UMBrC); p¼ 0.001 (for 5094M); p¼0.036 (for 5104M).
C. The expression of Smoothened and GLI1 was diminished in SUM1315 cells using shRNAs and the impact on NRP2 mRNA expression was quantified by qPCR.
p¼0.008, p¼ 0.005 (for Smo); p¼ 0.003, p¼ 0.02 (for GLI1); p¼0.004, p¼ 0.008 (for NRP2). The effect of Smoothened down-regulation on GLI1
mRNA expression was also measured using qPCR in LNCaP cells as a positive control (p¼ 0.001; p¼ 0.001).
D. The expression of Smoothened was diminished in SUM1315 cells using shRNAs and the effect of CA-FAK expression on GLI1 mRNA expression was quantified
by qPCR (p¼0.0039; p¼ 0.0047; p¼ 0.003).
E. Wild-type and dominant negative Ras (DN-Ras) constructs were expressed in SUM1315 cells and the effect on BMI-1 and GLI1 mRNA expression was
quantified by qPCR. p¼ 0.01 (for GLI1); p¼ 0.007 (for BMI-1).
F. The effect of Smoothened or Ras down-regulation on GLI1 mRNA expression was measured using qPCR. p¼0.0006; p¼0.007.
G. The NRP2low population of SUM1315 cells that expressed either a vector control or a CA-Ras construct (8 mice per group) was implanted in the mammary fat
pads of NSG mice and tumour formation was assessed by palpation. The curve comparison was done using Log-rank test (p¼0.0004).
H. The effect of GLI1 down-regulation in cells expressing either vector or a CA-Ras construct on mammosphere formation was measured (p¼ 0.02). Error bars
represent the mean SD for the in vitro experiments. Statistical differences between data groups were determined using Student’s t-test.
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because this integrin has been implicated in the function of
tumour stem cells (Lathia et al, 2010) and high a6 expression
characterizes tumour initiating populations (Friedrichs et al,
1995; Honeth et al, 2008; Lathia et al, 2010; Mulholland et al,
2009; Schober & Fuchs, 2011; Vieira et al, 2012). However, the
mechanism by which it functions in this context has been
elusive. We conclude that the ability of this integrin to activate
FAK and the consequent activation of Ras and induction of
GLI1 expression underlie its contribution to tumour initiation.
Indeed, our observation that an integrin involved in tumour
initiation regulates a Hh effector molecule that is also involved
in tumour initiation is novel and unexpected. The a6b1 integrin
functions primarily as a laminin receptor (Goel et al, 2012b), and
this function is supported by our finding that GLI1 expression
induces cell adhesion to laminin but not collagen and this
induction is dependent on a6b1. These observations support the
conclusion that laminin is an important component of thematrix
microenvironment that regulates the function of TICs and that
these interactions are mediated by a6b1 (Lathia et al, 2010). Our
data add a new dimension to the understanding of the role of
a6b1 in tumour initiation because they indicate that the function
of this integrin is regulated by VEGF/NRP2 signalling consistent
with our previous finding that NRP2 interacts specifically with
a6b1 and facilitates its association with the cytoskeleton and
localization in focal adhesions (Goel et al, 2012b).
Recent studies have demonstrated the importance of FAK in
breast cancer and the function of TICs (Ginestier et al, 2010; Luo
et al, 2009). For example, targeted deletion of FAK inhibited
tumourigenesis in a mouse model of mammary carcinoma and
reduced the pool of cancer stem/progenitor cells in these
tumours (Luo et al, 2009). The question that arises from these
seminal studies is how FAK contributes to these functions. Our
data reveal that FAK is essential because it regulates the
expression of BMI-1 by activating Ras and inducing GLI1
expression. The involvement of FAK in regulating BMI-1
expression does not exclude other contributions of this kinase
to the function of TICs, although its ability to induce GLI1 and,
consequently, BMI-1, provides an important mechanism for its
involvement in tumour formation.
The culmination of our study is the discovery that GLI1
functions at the nexus of the autocrine VEGF/NRP2 and
a6b1 signalling pathway that contributes to the initiation of
TNBC. This function of GLI1 is substantiated by our finding
that the expression of VEGF, NRP2 and GLI1 is significantly
higher in TNBC than in non-TNBC (Fig 9D). Other studies
have also implicated GLI1 in the function of tumour stem
or initiating cells (Liu et al, 2006; Varnat et al, 2009). The fact
GLI1 can regulate BMI-1 expression (Liu et al, 2006) also
strengthens its involvement in the function of TICs. As
mentioned, the ability of the a6b1 integrin to regulate
GLI1 expression was unexpected, as was our finding that
GLI1 regulates the function of a6b1 and its ability to function as
a laminin receptor. We postulate that the regulation of
a6b1 function by GLI1 is mediated by GLI1 regulation of
NRP2. This conclusion is supported by the reports that NRPs
are positive regulators of Hh signalling (Cao et al, 2008;
Hillman et al, 2011). Previously, we established the importance
of c-Jun in regulating NRP2 transcription (Goel et al, 2012a)
and we demonstrate here that c-Jun and GLI1 function
synergistically to regulate NRP2. Interestingly, GLI1 can
regulate c-Jun (Laner-Plamberger et al, 2009) suggesting that
the positive feedback inherent in our autocrine signalling
pathway would enhance both GLI1 and c-Jun, and impact NRP2
and a6b1.
An important issue that emerges from our findings is whether
canonical or non-canonical Hh signalling contributes to the
signalling pathway we describe. The data we present strongly
suggest the involvement of a non-canonical pathway because
down-regulation of Smoothened, a critical component of the
canonical pathway, did not inhibit autocrine signalling. This
observation is consistent with our conclusion that FAK-
mediated Ras activation drives GLI1 expression and it supports
previous studies that have implicated Ras in non-canonical
Hh signalling (Lauth & Toftgard, 2007; Stecca et al, 2007;
Varnat et al, 2009). Yet, we also found that exogenous Shh
increased mammosphere formation (Fig 6B). One interpretation
of these findings is that non-canonical GLI1 activation can
be amplified by canonical signalling. This possibility is
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Figure 7. NRP2/Ras regulate GLI1 predominantly by the ERK pathway.
A. The effect of SUFU downregulation on SUFU mRNA expression (p¼0.001; p¼ 0.001) and mammosphere formation (p¼0.01; p¼0.03) was measured in
the NRP2low population of SUM1315 cells.
B. The NRP2high population of SUM1315 cells was either transfected with DN-Ras or treated with the MEK inhibitor U0126 and mammosphere assays were
performed (p¼0.0001; p¼ 0.0002).
C. The NRP2low population of SUM1315 cells expressing either GFPsh or SUFU-sh was transfected with either control vector or CA-MEK and mammosphere
assays were performed. Immunoblot shows expression of HA-tagged CA-MEK (p¼ 0.001; p¼ 0.0003; p¼ 0.001).
D. A Flag-tagged dominant negative GLI1 construct (DN-GLI1) was expressed in SUM1315 cells and the effect on BMI-1 mRNA and protein expression was
determined (p¼0.001).
E. A GLI1 construct was expressed in the NRP2low population of epithelial cells freshly isolated from breast cancer biopsies (UMBrC) and the effect on BMI-1
expression was measured by immunoblotting (p¼ 0.0003).
F. A GLI1 construct was expressed in the NRP2low population of SUM1315 cells that also expressed either wild-type or DN-Ras, and the effect on BMI-1 mRNA
expression was quantified by qPCR.
G. The NRP2low population of SUM1315 cells that expressed either a vector control or a GLI1 construct (8 mice per group) were implanted in the mammary fat
pads of NSG mice and tumour formation was assessed by palpation. The curve comparison was done using the Log-rank test (p¼ 0.03).
H. The NRP2high population of SUM1315 cells that expressed either GFP-sh or GLI1-sh was implanted in the mammary fat pads of NSGmice and treated with IgG
or a-NRP2 (8 mice per group). Tumour formation was assessed by palpation. The curve comparison was done using the Log-rank test (p¼0.0001). Error bars
represent the mean SD for the in vitro experiments. Statistical differences between data groups were determined using Student’s t-test.
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supported by the reports that simultaneous activation of Ras
and Hh signalling caused extensive formation of intraepithelial
neoplasias and accelerated lethality in a transgenic model of
pancreatic carcinoma (Pasca di Magliano et al, 2006) and that
de-regulation of Ras signalling in mice lacking p53 increased
Shh expression (Hingorani et al, 2005). Moreover, our finding
that down-regulation of Smoothened reduced FAK-mediated
up-regulation of GLI1 (Fig 6D) supports this hypothesis.
Our conclusion that GLI1 is induced by a NRP2-mediated Ras
pathway should be discussed in the context of the existing
literature on how Rasmediates GLI1 activation. Ras can regulate
the nuclear localization of GLI1 via SUFU based on the report
that enhanced levels of SUFU prevented nuclear localization of
GLI induced by oncogenic Ras (Stecca et al, 2007). However,
SUFU does not appear to have a major role in NRP2-mediated
GLI1 activation based on our data. Our results do agree with the
finding that Ras mediates GLI1 activity via the MEK/ERK
pathway and they implicate NRP2 as amediator of this pathway.
Although there is evidence that p53 inhibits the activity and
nuclear translocation of GLI1 (Stecca and Ruiz i Altaba, 2009),
this mode of GLI1 regulation is probably not relevant for our
findings because TNBC is predominantly p53 mutant (Kumar
et al, 2012; Network, 2012).
Finally, the data presented have significant implications for
therapy of breast cancer, especially TNBC (Caunt et al, 2008).
Specifically, targeting NRP2 could be effective in reducing
tumour burden and recurrence because it will disrupt an
autocrine signalling pathway that is necessary for the function of
TICs, in addition to inhibiting lymphangiogenesis as previously
suggested (Caunt et al, 2008). Indeed, our finding that NRP2 Ab
treatment of tumours reduced tumour volume but it did not
inhibit tumour angiogenesis significantly suggests that anti-
NRP2 therapy could be highly effective when used in
conjunction with anti-angiogenesis therapies for the clinical
management of breast cancer.
MATERIALS AND METHODS
Reagents and antibodies
Matrigel and collagen I were purchased from BD Biosciences (San Jose,
CA, USA) and laminin-1 (LN-1 or LN-111) was purchased from
Invitrogen (Carlsbad, CA, USA); PF573228 (Tocris). The following Abs
were used: a6 (AA6A, provided by Anne Cress; and GoH3, purchased
from Millipore); NRP2 (goat IgG, R&D; C9 and H300, Santa Cruz,
Santa Cruz, CA, USA); actin (Sigma); p-FAK Y397 (mouse IgG, BD
Bioscience) and FAK (Santa Cruz); EpCAM (AbCaM); Flag (Sigma); ki-67
(NovoCastra); HA (Roche); CD31 (Santacruz); p-ERK, ERK and GLI1 (Cell
Signaling); BMI-1 (Cell Signaling) and VEGF (Calbiochem). A function-
blocking NRP2 Ab (Anti-Nrp2B) was provided by Genentech (Caunt
et al, 2008).
Isolation of epithelial cells from breast tumours
Human breast tissue was obtained in compliance with the
Institutional Review Board of the University of Massachusetts
Medical School. Epithelial cells were isolated from discarded
but freshly resected, invasive breast tumours as described
(Fillmore et al, 2010). Briefly, the tissue was minced and digested
overnight with a mixture of collagenase (Roche, Indianapolis, IN, USA)
and hyaluronidase (MP Biomedicals, Solon, OH, USA). The digested
cells were plated briefly in serum (1–2 h) to deplete mammary
fibroblasts. The organoids were dissociated into a single cell
suspension by trypsinization and filtered (40-mm filter; BD
Biosciences) to remove residual clustered cells. Immediately
after dissociation, cells were sorted based on EpCAM, a6 and
NRP2 expression, and subsequently analysed by either immunoblot-
ting or FACS. Ascites fluid was collected from breast cancer
patients (5094M and 5104M) with metastatic disease. Malignant
cells were pelleted by centrifuging ascitic fluid diluted with PBS. The
cell pellet was washed several times with PBS and tumour cells
were separated using Ficoll. 5094M is ERþ/PR and 5104M is
ERþ/PRþ/Her2.
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Figure 8. GLI1 stimulates an autocrine loop involving VEGF/NRP2 and the a6b1 integrin.
A. Mammary tumours isolated from transgenic mice that express either GLI1 or PyV-MT under the regulation of the MMTV promoter were analysed for
expression of VEGF, NRP2 and BMI-1 by qPCR. p¼0.002, p¼ 0.006 (for VEGF); p¼ 0.01, p¼ 0.01 (for NRP2); p¼0.029, p¼0.001 (for BMI-1).
B. A GLI1 construct was expressed in the NRP2low population of SUM1315 cells and the effect on NRP2 expression was assayed by immunoblotting.
C. GLI1 expression was depleted by shRNAs in the NRP2high SUM1315 population and NRP2 expression was measured by immunoblotting (p¼0.001).
D. A GLI1 construct was expressed in the NRP2low population of SUM1315 cells and the ability of these cells to adhere to laminin or collagen in the presence
of an a6 blocking Ab or control IgG was assayed.
E,F. GLI1 expression in the NRP2high population of SUM1315 cells was depleted using shRNAs (GLI1-sh-1 and GLI1-sh-2), and the ability of these cells to adhere
to either laminin or collagen (5 or 10mg/ml) was assessed (E). p¼ 0.003, p¼0.002 (for LN, 5mg/ml); p¼ 0.008, p¼0.01 (for LN, 10mg/ml). Extracts
from these populations were immunoblotted to verify GLI1 knockdown (F).
G. GLI1 expression was depleted by shRNAs in the NRP2high populations isolated from SUM1315 cells and human breast biopsies (UMBrC) and the effect on
FAK expression and phosphorylation (pY397) was assessed by immunoblotting.
H. A GLI1 construct was expressed in the NRP2low population of SUM1315 cells. These transfectants were used to assay NRP2 promoter activity using luciferase
reporter constructs that contained the wild-type promoter or mutations in the AP-1 and GLI1-binding sites. The above experiments were repeated at least
twice (p¼0.008; p¼0.02; p¼0.004).
I. Freshly isolated tumour cells fromMMTV-GLI1mice (two independent tumours) were infected with either GFP or NRP2 shRNAs (8mice per group). These cells
were implanted in the mammary fat pads of NSGmice and tumour formation was assessed by palpation. The curve comparison was done using the Log-rank
test (p¼ 0.0008; p¼ 0.02). Error bars represent the mean SD for the in vitro experiments. Statistical differences between data groups were determined
using Student’s t-test.
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Figure 9. NRP2 inhibition impacts established tumours.
A. SUM1315 cells were implanted into mammary fat pads of NSGmice. Once tumours reached a volume of 250mm3 as determined by caliper measurement, the
mice were injected i.p. with either Anti-Nrp2B or control IgG (twice weekly; 5 mice per group) and tumour volume was measured at regular intervals. Tumour
growth was analysed bymeasuring tumour volume. Anti-Nrp2B treatment resulted in a statistically significant inhibition of tumour volume. p¼0.05 (day 17);
p¼ 0.008 (day 21); p¼ 0.002 (day 24).
B. Formalin-fixed and paraffin-embedded sections from SUM1315 tumours treated with either either Anti-Nrp2B or control IgG (n¼3) were immunostained for
either Ki-67 or CD31. Scale bar¼ 100mm.
C. CD31 staining was quantified to provide an indication of tumour angiogenesis. Quantification was done using 20 images from each group (p¼ 0.5).
D. Frozen clinical specimens from TPN (n¼ 32) or non-TPN (n¼ 35) breast tumours were used to compare the mRNA levels of NRP2, VEGF and GLI1 by qPCR.
E. Frozen clinical specimens from TPN (n¼ 21) or non-TPN (n¼21) were used to compare the protein levels of pFAK by immunoblotting. A graph summarizing the
densitometric analysis of the immunoblots is shown.
F. Schematic model depicting the major conclusions of this study. Error bars represent the mean SD for all panels. Statistical differences between data groups
were determined using Student’s t-test.
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Cell lines
SUM1315, SUM149 and SUM159 cells were provided by Dr. Steve
Ethier (Wayne State University School of Medicine). MCF-10A and
MCF-10AT were obtained from the Barbara Ann Karmanos Cancer
Institute (Detroit, MI, USA). HMECs were purchased from Lonza
Bioscience and HMLE-PR cells were provided by Dr. Weinberg
(Whitehead Institute).
Molecular reagents
Lentiviruses containing shRNAs specific for NRP2 (clone ID
TRCN0000063308, TRCN0000063309 or TRCN0000063312), a6 integrin
(TRCN0000057777, TRCN0000057776); GLI1 (TRCN0000020484,
TRCN0000020488); Smoothened (TRCN0000014366 and
TRCN0000014367) or GFP (RHS4459) were obtained from Open
Biosystems (Huntsville, AL, USA). A lentiviral plasmid (FUGW)
expressing BMI-1 was obtained from Addgene. A constitutively active
FAK construct was provided by Jun-Lin Guan (University of Michigan
Medical School). Wild-type and dominant negative Ras constructs
were described previously (Yoon et al, 2006). Wild-type GLI1 and Gli3T
(dominant negative GLI1, (Rajurkar et al, 2012)) constructs were
provided by Dr. Junhao Mao. A NRP2 plasmid was obtained from
Dr. Tsai (Baylor College of Medicine) and mutations in the b1 and b2
domains of NRP2 were made in this plasmid using SLIC cloning (Li &
Elledge, 2007). A NRP2 promoter luciferase construct (3000/þ195)
or the same construct with AP1 mutations was described
previously (Goel et al, 2012a). A mutation in the GLI1 binding site
(ACCACCCA to AAAAAAAA) in these constructs was generated using
Quickchange XL Site-directed Mutagenesis kit (Agilent Technologies).
A construct expressing constitutively active Ras was obtained from
Addgene.
Cell-based assays
Cell adhesion assays were performed as described previously (Goel
et al, 2012b). Flow cytometry was used to quantify surface expression
of the a6 integrin and NRP2 in SUM1315 and UMBrC cells. The gating
strategy for isolating luminal (CD44þ/CD24þ/EpCamþ) and stem-like
(CD44þ/CD24/EpCAMþ) populations in Fig. 1 was described pre-
viously (Gupta et al, 2011).
To generate mammospheres, single-cell suspensions were maintained
in DMEM-F12 medium supplemented with B27 (1:50; Invitrogen),
EGF (20ng/ml), basic fibroblast growth factor (20 ng/ml;bFGF), and
heparin (10mg/ml) in Costar 3471 six-well plates at a density of
2104 cells/ml. In some experiments, mammospheres were collected
by centrifugation and dissociated with 0.05% trypsin for 15min to
obtain single-cell suspensions (Liao et al, 2007).
Immunoblotting and qPCR
Cells were extracted in either a Triton-X-100 buffer (1% Triton X-100,
150mM NaCl, 50mM Tris–HCl, pH 7.5, 1mM PMSF and protease
inhibtors) or RIPA (50mM Tris–HCl, pH 7.4, 150mM NaCl, 0.1% SDS,
0.5% sodium deoxycholate, 1mM PMSF and protease inhibitors). The
proteins were separated by SDS–PAGE and immunoblotted using Abs
as specified in the figure legends. For qPCR, RNA was isolated using
RNeasy kit (Qiagen) and converted to cDNA using Transcriptor First
Strand cDNA Synthesis kit (Roche). We performed qPCR with a SYBR
Green PCR master mix using an ABI Prism 7900HT instrument
(Applied Biosystems).
Xenograft experiments
SUM1315 cells were mixed with Matrigel at a 10-fold dilution
and injected into a mammary fat pad of immunocompromised
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The paper explained
PROBLEM:
Highly aggressive forms of breast carcinoma are difficult to treat
because they progress rapidly and are resistant to most
chemotherapeutic drugs. The reason for their aggressive
behaviour and drug resistance is that these tumours contain a
high number of cells that have the ability to form new tumours,
cells that are referred to as tumour initiating or stem cells. These
cells also have the propensity to metastasize. For these reasons,
TICs are ideal targets for therapy but much more needs to be
known about the mechanisms that contribute to their function.
RESULTS:
We establish that TICs present in highly aggressive breast
carcinomas require autocrine VEGF signalling mediated by the
receptor neuropilin-2 (NRP2) for their function. Furthermore, we
define a signalling cascade initiated by VEGF/NRP2 signalling
that culminates in the regulation of a key stem cell factor BMI-1
that is critical for tumour initiation. This signalling cascade
involves the ability of VEGF/NRP2 signalling to activate the a6b1
integrin and, consequently, FAK. FAK-mediated activation of Ras/
MEK signalling enhances expression of the Hedgehog effector
GLI1 that can induce BMI-1. Importantly, GLI1 also stimulates
NRP2 expression, establishing a positive feedback loop that
sustains this autocrine pathway. The significance of these data is
evidenced by the fact that inhibition of NRP2 prevents tumour
initiation and it causes regression of established tumours.
IMPACT:
The data presented provide a novel mechanism that contributes
to the initiation of aggressive breast carcinomas. This
mechanism integrates the function of several key molecules that
have been implicated in the function of tumour stem cells.
Importantly, these findings provide a strong rationale for the use
of anti-NRP2 therapy for the treatment of aggressive breast
carcinomas.
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NOD.Cg-Prkdcscid IL2rgtm1Wjl (abbreviated as NSG) mice. Tumour onset
was determined by palpation. In some experiments, SUM1315
xenografts were treated intraperitoneally (i.p.) with either control
IgG or a NRP2 Ab (Anti-Nrp2B) at dose of 40mg/kg (twice weekly). In
some experiments, NRP2low population of SUM1315 cells expressing
either a control vector or GLI1 construct were injected in the
mammary fat pad of NSG mice and tumour onset was determined. To
study the role of NRP2 in MMTV-Gli tumours, primary tumour cells
from MMTV-GLI1 mammary tumours were infected with either NRP2
or GFP shRNAs and injected orthotopically in NSG mice. Tumour onset
was used as the endpoint for these studies.
Transgenic mice
MMTV-PyV-MT mice transgenic for the polyoma virus middle T (PyV-
MT) antigen under the control of the MMTV promoter (Jackson
Laboratory) were obtained from Dr. Leslie Shaw. Cells from these mice
are isolated and maintained as described before (Nagle et al, 2004).
The TgMFT121; Brca1f/f p53f/f; TgWAP-Cre (TBP) model was generated
and described before (Kumar et al, 2012). In brief, TgMFT121 (MMTV-
Floxed-eGFP-T121) were generated to conditionally inactivate the pRb
family of proteins in mammary epithelium. TgMFT121 mice were
crossed with TgWAp-Cre, Brca1f/f and p53f/f (NCI Mouse Repository
Frederick) to generate female TgMFT121; Brca1f/f p53f/f; TgWAP-Cre
mice, this approach inactivate pRB family proteins, Brca1 and p53
specifically in mammary epithelial cells via the Wap-Cre transgene. All
mouse strains used to generate TBP mice were backcrossed to FVB
background for 10 generations.
The MMTV-GLI1 transgenic mouse model was generated and
described before (Fiaschi et al, 2009). These mice express transgenic
GLI1 in the presence of doxycycline, which was added to drinking
water with 5% sucrose. All animal experiments were in accordance
with institutional guidelines and are approved by IACUC.
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